Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Biomedicines|August 27, 2021
Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 PathwayShin-Yi Chung, Yi-Ping Hung, Yi-Ru Pan, et al.
BMC Research Notes|January 28, 2012
Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort studyKuo-Wei Chen, Chia-Jen Liu, Hsueh-Ju Lu, et al.
Cell Communication and Signaling : CCS|December 27, 2022
BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell deathHuey-Jiun Ko, Shean-Jaw Chiou, Cheng-Yu Tsai, et al.
Cancer Medicine|October 21, 2025
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II TrialMuh-Hwa Yang, Shang-Yin Wu, I-Wei Ho, et al.
Cell Death Discovery|January 27, 2025
Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancerYen-Han Tseng, Trieu Thi My Tran, Jinghua Tsai Chang, et al.
Oncotarget|January 27, 2018
Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patientsChun-Nan Yeh, Yu-Chan Chang, Yeu Su, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapyKien Thiam Tan, Chun-Nan Yeh, Yu-Chan Chang, et al.
EJNMMI Research|May 24, 2019
A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of <sup>188</sup>Re-liposome in patients with metastatic tumorsShyh-Jen Wang, Wen-Sheng Huang, Chi-Mu Chuang, et al.
The Lancet. Oncology|April 1, 2021
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialNancy Y Lee, Robert L Ferris, Amanda Psyrri, et al.
Oncotarget|June 20, 2015
Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinomaMing-Huang Chen, Chueh-Chuan Yen, Chi-Tung Cheng, et al.
Pageof 13